Wyeth Seeking "Novel" Partnerships For Oncology Pipeline
This article was originally published in The Pink Sheet Daily
The company has 13 drugs in development for oncology indications, "far more" than it can afford to develop on its own. Wyeth is not interested in out-licensing or divesting the candidates but instead will pursue a "novel" development partnership.
You may also be interested in...
Changes to the R&D process include refocusing efforts on discovery of new molecular entities, with a reduced emphasis on line extensions. Only 23% of Wyeth’s portfolio is made up of line extensions versus 45% in 2001. Wyeth is also beginning to link scientist compensation to R&D goals.
The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.
Following the June 6 bid submission deadline, CMS expects to have multiple drug plans in every region. Administrator McClellan declines to provide exact number of Part D bids.